Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atea Pharmaceuticals, Inc. (AVIR)

Atea Q3 2026 net loss narrows to $32.2 million; Hercules facility up to $200 million

Positive Impact 3 of 5 earnings

Atea Pharmaceuticals reported a third-quarter 2026 net loss of $32.2 million, or $0.40 per share, down from $42.0 million, or $0.53 per share, a year earlier, as research and development spending fell. The company also secured a credit facility with Hercules Capital of up to $200 million, of which $65 million was drawn on November 6, 2026, and said current resources fund operations into mid-2028.

Key points

  • Net loss was $32.2 million, or $0.40 per share, for the three months ended September 30, 2026, versus $42.0 million, or $0.53 per share, a year earlier.
  • Cash, cash equivalents and marketable securities were $191.2 million at September 30, 2026, versus $301.8 million at December 31, 2025.
  • Hercules Capital facility of up to $200 million; $65 million drawn at closing on November 6, 2026, with up to $135 million more subject to milestones.
  • Phase 3 C-BEYOND trial met its primary endpoint: 93.91% SVR for BEM/RZR versus 94.75% for Epclusa; C-FORWARD topline results expected in early 2027.

The filing

CompanyAtea Pharmaceuticals, Inc. (AVIR)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:17 PM ET
Accession number0001193125-26-453636

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.